Muthulakshmi Avudaiappan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muthulakshmi Avudaiappan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra E. Butler
Royal College of Surgeons of Ireland, Adliya, Bahrain
1 shared publication - Hamna Hameetha Begam
Research Department, Royal College of Surgeons in Ireland-Bahrain, Adliya 15503, Bahrain
1 shared publication - Manjula Nandakumar
Research Department, Royal College of Surgeons in Ireland, Medical University in Bahrain, Adliya P.O. Box 15503, Bahrain
1 shared publication - Manyam Praveen Kumar
School of Postgraduate Studies & Research, Royal College of Surgeons in Ireland (RCSI), Medical University of Bahrain, Busaiteen 228, Bahrain
1 shared publication - Sana Waris
Research Department, Royal College of Surgeons in Ireland, Medical University in Bahrain, Adliya P.O. Box 15503, Bahrain
1 shared publication - Zahra Husain I. Abdulrasool
School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Adliya 15503, Bahrain
1 shared publication
Latest Publications
- Open Access
Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Diabetes mellitus encompasses a heterogeneous group of metabolic disorders defined by abnormalities in insulin secretion, function, or both. Exogenous insulin therapy has long been the principal treatment strategy for patients with type 1 diabetes and for those in advanced stages of type 2 diabetes. Stem cell therapy has gained significant attention in recent years as a potential curative approach for several life-threatening disorders. In this review, we focus on the use of induced pluripotent stem cells as an alternative source for beta-cell generation, offering a solution to organ scarcity and providing a sustainable supply of insulin-producing cells. We further evaluate current developments in encapsulation technologies and transplantation sites, while noting that the issue of immune-mediated graft rejection continues to be widely debated. The aim of this review is to outline encapsulation techniques and transplantation approaches explored in animal models, and to discuss the risks and challenges anticipated in human clinical trials.
Open AccessStem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Diabetes mellitus encompasses a heterogeneous group of metabolic disorders defined by abnormalities in insulin secretion, function, or both. Exogenous insulin therapy has long been the principal treatment strategy for patients with type 1 diabetes and for those in advanced stages of type 2 diabetes. Stem cell therapy has gained significant attention in recent years as a potential curative approach for several life-threatening disorders. In this review, we focus on the use of induced pluripotent stem cells as an alternative source for beta-cell generation, offering a solution to organ scarcity and providing a sustainable supply of insulin-producing cells. We further evaluate current developments in encapsulation technologies and transplantation sites, while noting that the issue of immune-mediated graft rejection continues to be widely debated. The aim of this review is to outline encapsulation techniques and transplantation approaches explored in animal models, and to discuss the risks and challenges anticipated in human clinical trials.